NDAORALLIQUID
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
RAVICTI (glycerol phenylbutyrate) by Amgen. Approved for developmental and epileptic encephalopathy, stxbp1 encephalopathy, parkinson's disease. First approved in 2013.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAVICTI (glycerol phenylbutyrate) is an oral liquid medication approved by the FDA in February 2013 for the treatment of urea cycle disorders. It functions as a nitrogen-binding agent that provides an alternative pathway for nitrogen excretion, reducing ammonia levels in patients who cannot effectively process nitrogen through the normal urea cycle. The drug addresses a critical unmet need in a rare disease population where hyperammonemia poses severe neurological risks.
$0.1BPart D
5.8 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Investigational (3)
Worked on RAVICTI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.